JP2017535267A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535267A5 JP2017535267A5 JP2017525893A JP2017525893A JP2017535267A5 JP 2017535267 A5 JP2017535267 A5 JP 2017535267A5 JP 2017525893 A JP2017525893 A JP 2017525893A JP 2017525893 A JP2017525893 A JP 2017525893A JP 2017535267 A5 JP2017535267 A5 JP 2017535267A5
- Authority
- JP
- Japan
- Prior art keywords
- arenavirus
- segment
- utr
- control
- under
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000712891 Arenavirus Species 0.000 claims description 215
- 239000002245 particle Substances 0.000 claims description 102
- 239000000427 antigen Substances 0.000 claims description 40
- 102000036639 antigens Human genes 0.000 claims description 40
- 108091007433 antigens Proteins 0.000 claims description 40
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 230000002458 infectious effect Effects 0.000 claims description 14
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 13
- 239000002299 complementary DNA Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 10
- 229960005486 vaccine Drugs 0.000 claims description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 6
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 6
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 108091006047 fluorescent proteins Proteins 0.000 claims description 6
- 102000034287 fluorescent proteins Human genes 0.000 claims description 6
- 239000005090 green fluorescent protein Substances 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 241000701022 Cytomegalovirus Species 0.000 claims description 5
- 241000711549 Hepacivirus C Species 0.000 claims description 5
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 5
- 239000013566 allergen Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 108010054624 red fluorescent protein Proteins 0.000 claims description 5
- 108020004635 Complementary DNA Proteins 0.000 claims description 4
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 3
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims description 3
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 claims description 3
- 208000037581 Persistent Infection Diseases 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- 108010077753 type II interferon receptor Proteins 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 description 13
- 230000035897 transcription Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 241000712890 Junin mammarenavirus Species 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000017143 RNA Polymerase I Human genes 0.000 description 3
- 108010013845 RNA Polymerase I Proteins 0.000 description 3
- 102000009572 RNA Polymerase II Human genes 0.000 description 3
- 108010009460 RNA Polymerase II Proteins 0.000 description 3
- 230000002457 bidirectional effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 102000001183 RAG-1 Human genes 0.000 description 2
- 108060006897 RAG1 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462079493P | 2014-11-13 | 2014-11-13 | |
| US62/079,493 | 2014-11-13 | ||
| PCT/EP2015/076458 WO2016075250A1 (en) | 2014-11-13 | 2015-11-12 | Tri-segmented arenaviruses as vaccine vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201083A Division JP2021045154A (ja) | 2014-11-13 | 2020-12-03 | ワクチンベクターとしての３分節型アレナウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535267A JP2017535267A (ja) | 2017-11-30 |
| JP2017535267A5 true JP2017535267A5 (enExample) | 2018-12-27 |
| JP6805139B2 JP6805139B2 (ja) | 2020-12-23 |
Family
ID=54545130
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525893A Active JP6805139B2 (ja) | 2014-11-13 | 2015-11-12 | ワクチンベクターとしての３分節型アレナウイルス |
| JP2020201083A Pending JP2021045154A (ja) | 2014-11-13 | 2020-12-03 | ワクチンベクターとしての３分節型アレナウイルス |
| JP2023000345A Active JP7796680B2 (ja) | 2014-11-13 | 2023-01-05 | ワクチンベクターとしての３分節型アレナウイルス |
| JP2025138430A Pending JP2025170342A (ja) | 2014-11-13 | 2025-08-21 | ワクチンベクターとしての３分節型アレナウイルス |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201083A Pending JP2021045154A (ja) | 2014-11-13 | 2020-12-03 | ワクチンベクターとしての３分節型アレナウイルス |
| JP2023000345A Active JP7796680B2 (ja) | 2014-11-13 | 2023-01-05 | ワクチンベクターとしての３分節型アレナウイルス |
| JP2025138430A Pending JP2025170342A (ja) | 2014-11-13 | 2025-08-21 | ワクチンベクターとしての３分節型アレナウイルス |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10722564B2 (enExample) |
| EP (2) | EP3778903B1 (enExample) |
| JP (4) | JP6805139B2 (enExample) |
| CN (2) | CN107223130B (enExample) |
| AU (3) | AU2015345080B2 (enExample) |
| CA (1) | CA2967720C (enExample) |
| CY (1) | CY1123339T1 (enExample) |
| DK (2) | DK3778903T3 (enExample) |
| ES (2) | ES2811093T3 (enExample) |
| FI (1) | FI3778903T3 (enExample) |
| HR (2) | HRP20201684T1 (enExample) |
| HU (1) | HUE051390T2 (enExample) |
| LT (2) | LT3218504T (enExample) |
| PL (2) | PL3218504T3 (enExample) |
| PT (2) | PT3778903T (enExample) |
| RS (1) | RS60937B1 (enExample) |
| SI (2) | SI3778903T1 (enExample) |
| WO (1) | WO2016075250A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103993012B (zh) | 2007-12-27 | 2023-01-10 | 苏黎士大学 | 复制缺陷型沙粒病毒载体 |
| RS61993B1 (sr) * | 2013-12-03 | 2021-07-30 | Hookipa Biotech Gmbh | Cmv vakcine |
| ES2811093T3 (es) | 2014-11-13 | 2021-03-10 | Univ Geneve | Arenavirus trisegmentados como vectores de vacunas |
| HK1246183A1 (zh) * | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| WO2018045029A1 (en) * | 2016-09-02 | 2018-03-08 | The United States Of America, As Represented By The Secretary Of The Army | Pan south american arenavirus live attenuated vaccine |
| WO2017076988A1 (en) * | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| EP3373959B1 (en) | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| CN110167586B (zh) * | 2016-11-04 | 2024-01-30 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒 |
| CN110719788A (zh) * | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| CN108611310A (zh) * | 2018-04-28 | 2018-10-02 | 中国药科大学 | 一种重组Hsp65与STEAP1186-193融合蛋白的基因工程菌的构建 |
| CN108977434A (zh) * | 2018-07-03 | 2018-12-11 | 张罗 | 鼻腔脱落细胞rna的提取方法 |
| WO2020255023A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| CN114981443A (zh) * | 2019-11-07 | 2022-08-30 | 巴塞尔大学 | 作为载体的沙粒病毒 |
| IL298420A (en) | 2020-05-29 | 2023-01-01 | Hookipa Biotech Gmbh | Cancer treatment strategies using RNA virus vectors |
| CA3202466A1 (en) | 2021-01-14 | 2022-07-21 | Jiani LI | Hiv vaccines and methods of using |
| WO2022159664A1 (en) * | 2021-01-22 | 2022-07-28 | Chan Zuckerberg Biohub, Inc. | Engineered multi-segmented rna viruses for large-scale combinatorial genetic screening |
| MX2023011054A (es) | 2021-03-23 | 2023-11-22 | Hookipa Biotech Gmbh | Arenavirus utilizados en tratamientos del cáncer de próstata. |
| EP4337320A1 (en) | 2021-05-13 | 2024-03-20 | Hookipa Biotech GmbH | Arenaviruses as vectors |
| US20250073324A1 (en) | 2021-11-08 | 2025-03-06 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies |
| CN114231562A (zh) * | 2021-12-15 | 2022-03-25 | 中国科学院武汉病毒研究所 | 一种表达荧光素酶基因的淋巴脉络丛脑膜炎病毒及其构建方法和应用 |
| EP4475879A1 (en) | 2022-02-08 | 2024-12-18 | Hookipa Biotech GmbH | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| AU2024343172A1 (en) | 2023-09-15 | 2026-03-05 | Gilead Sciences, Inc. | Arenavirus formulations, methods and uses thereof |
| WO2025191169A1 (en) | 2024-03-15 | 2025-09-18 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US8158413B2 (en) * | 2005-10-17 | 2012-04-17 | Institut Pasteur | Lentiviral vector-based vaccine |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| CN103993012B (zh) | 2007-12-27 | 2023-01-10 | 苏黎士大学 | 复制缺陷型沙粒病毒载体 |
| GB201001726D0 (en) * | 2010-02-03 | 2010-03-24 | Univ St Andrews | Bunyavirus vaccine |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| CN104159607A (zh) | 2012-01-24 | 2014-11-19 | 桑福德研究院/南达科他大学 | 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸 |
| US9809801B2 (en) | 2013-03-15 | 2017-11-07 | Université De Genève | Anti-mycobacterial vaccines |
| GB201305361D0 (en) | 2013-03-25 | 2013-05-08 | Univ Edinburgh | Enhanced expression |
| RS61993B1 (sr) | 2013-12-03 | 2021-07-30 | Hookipa Biotech Gmbh | Cmv vakcine |
| US10342861B2 (en) | 2014-05-27 | 2019-07-09 | University Of Rochester | Arenavirus vaccine |
| US9943585B2 (en) | 2014-07-30 | 2018-04-17 | University Of Rochester | Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV) |
| BR112017005744B1 (pt) * | 2014-09-22 | 2023-11-28 | Regents Of The University Of Minnesota | "vírus pichinde geneticamente manipulado, método de fabricação e uso do mesmo, partícula viral infecciosa, composição, coleção de vetores, sistema de genética reversa e método de uso do mesmo" |
| GB201419572D0 (en) | 2014-11-03 | 2014-12-17 | Pirbright Inst The | Virus |
| ES2811093T3 (es) | 2014-11-13 | 2021-03-10 | Univ Geneve | Arenavirus trisegmentados como vectores de vacunas |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| HK1246183A1 (zh) | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| US10849969B2 (en) | 2015-10-23 | 2020-12-01 | Institut Pasteur | Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity |
| WO2017076988A1 (en) | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| EP3373959B1 (en) | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| IL262963B2 (en) | 2016-05-18 | 2025-01-01 | Hookipa Biotech Gmbh | Trisegmented PICHINDE viruses as vaccine vectors |
| CN110167586B (zh) | 2016-11-04 | 2024-01-30 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒 |
| CN110719788A (zh) | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
-
2015
- 2015-11-12 ES ES15794900T patent/ES2811093T3/es active Active
- 2015-11-12 CN CN201580073235.6A patent/CN107223130B/zh active Active
- 2015-11-12 HR HRP20201684TT patent/HRP20201684T1/hr unknown
- 2015-11-12 PL PL15794900T patent/PL3218504T3/pl unknown
- 2015-11-12 AU AU2015345080A patent/AU2015345080B2/en active Active
- 2015-11-12 LT LTEP15794900.9T patent/LT3218504T/lt unknown
- 2015-11-12 PL PL20184468.5T patent/PL3778903T3/pl unknown
- 2015-11-12 ES ES20184468T patent/ES3067019T3/es active Active
- 2015-11-12 CN CN202610136343.3A patent/CN122036892A/zh active Pending
- 2015-11-12 DK DK20184468.5T patent/DK3778903T3/da active
- 2015-11-12 DK DK15794900.9T patent/DK3218504T3/da active
- 2015-11-12 HR HRP20260167TT patent/HRP20260167T1/hr unknown
- 2015-11-12 SI SI201532094T patent/SI3778903T1/sl unknown
- 2015-11-12 EP EP20184468.5A patent/EP3778903B1/en active Active
- 2015-11-12 EP EP15794900.9A patent/EP3218504B1/en active Active
- 2015-11-12 RS RS20201251A patent/RS60937B1/sr unknown
- 2015-11-12 JP JP2017525893A patent/JP6805139B2/ja active Active
- 2015-11-12 CA CA2967720A patent/CA2967720C/en active Active
- 2015-11-12 LT LTEP20184468.5T patent/LT3778903T/lt unknown
- 2015-11-12 US US15/526,211 patent/US10722564B2/en active Active
- 2015-11-12 WO PCT/EP2015/076458 patent/WO2016075250A1/en not_active Ceased
- 2015-11-12 PT PT201844685T patent/PT3778903T/pt unknown
- 2015-11-12 PT PT157949009T patent/PT3218504T/pt unknown
- 2015-11-12 HU HUE15794900A patent/HUE051390T2/hu unknown
- 2015-11-12 SI SI201531397T patent/SI3218504T1/sl unknown
- 2015-11-12 FI FIEP20184468.5T patent/FI3778903T3/fi active
-
2020
- 2020-07-07 US US16/922,489 patent/US20210145950A1/en not_active Abandoned
- 2020-09-16 CY CY20201100879T patent/CY1123339T1/el unknown
- 2020-12-03 JP JP2020201083A patent/JP2021045154A/ja active Pending
-
2022
- 2022-01-06 AU AU2022200061A patent/AU2022200061A1/en not_active Abandoned
-
2023
- 2023-01-05 JP JP2023000345A patent/JP7796680B2/ja active Active
- 2023-11-13 US US18/507,584 patent/US20240082376A1/en not_active Abandoned
-
2024
- 2024-11-06 AU AU2024259760A patent/AU2024259760A1/en active Pending
-
2025
- 2025-08-21 JP JP2025138430A patent/JP2025170342A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516410A5 (enExample) | ||
| JP2023012463A5 (enExample) | ||
| JP2021182922A5 (enExample) | ||
| HRP20201684T1 (hr) | Tri-segmentirani arenavirusi kao vektori cjepiva | |
| JP2018536433A5 (enExample) | ||
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| Lasaro et al. | New insights on adenovirus as vaccine vectors | |
| Afkhami et al. | Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens | |
| HU | Baculovirus as a highly efficient expression vector in insect and mammalian cells | |
| Marsian et al. | Molecular pharming—VLPs made in plants | |
| FI2604695T3 (fi) | Replikaatiokyvyttömiä arenavirusvektoreita | |
| HRP20211015T1 (hr) | Cjepivo protiv citomegalovirusa (cmv) | |
| JP2018518172A5 (enExample) | ||
| JP2011182797A5 (enExample) | ||
| JP2011507536A5 (enExample) | ||
| WO2020076820A3 (en) | Compositions and methods for preparing viral vectors | |
| NZ514132A (en) | Stable recombinant influenza viruses free of helper viruses | |
| JP2025169249A5 (enExample) | ||
| CA3230406A1 (en) | Utilization of micro-rna for downregulation of cytotoxic transgene expression by modified vaccinia virus ankara (mva) | |
| AU2018392826B2 (en) | Lassa vaccine | |
| CN101278042B (zh) | 新型重组人丙型肝炎病毒样颗粒及其生产方法 | |
| RU2020125098A (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
| Kim et al. | Application of attenuated coxsackievirus B3 as a viral vector system for vaccines and gene therapy | |
| TWI908952B (zh) | 具有提升免疫原性之經修飾副痘病毒（一） | |
| Bowick et al. | Vaccine and adjuvant design for emerging viruses: mutations, deletions, segments and signaling |